MedImpact is not requiring patients currently taking Humira to switch, and all three products are on a preferred tier. MedImpact Healthcare Systems is providing access to two Humira biosimilars: ...

Symptoms of multiple sclerosis are generally the same, regardless of how old you are when it develops. The differences lie in which symptoms you're more likely to have and how quickly they get ...

Natalizumab (Tysabri) and ocrelizumab (Ocrevus) are options if other drugs don't work for you. Natalizumab prevents immune cells from getting to your brain and spinal cord, where they can damage ...

Beginning in 2025, Express Scripts will favor biosimilars of Humira, including its own private-label version. Beginning in 2025, Express Scripts will remove Humira (adalimumab) from its commercial ...

It could also mount a challenge to Roche’s fast-growing MS therapy Ocrevus (ocrelizumab). Novartis already markets the CD20-targeting drug for chronic lymphocytic leukaemia (CLL) as Arzerra ...

During the first half of this year, Ocrevus generated 1.04 billion Swiss francs – more than 90% of that was from use in the US. Roche’s MS drug Ocrevus earns blockbuster status a year after ...